AMPH vs TBPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.
TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.
Compare Another Pair
Related Comparisons
AMPH vs TBPH: Head-to-Head Comparison
This page compares Amphastar Pharmaceuticals, Inc. (AMPH) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.